Molecular profiling of tumor tissue using targeted clinical proteomics

使用靶向临床蛋白质组学对肿瘤组织进行分子分析

• 批准号: 8349470
• 负责人: Donald Johann
• 金额: $ 10.19万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349470
• 关键词: Biological Markers; Blood; Cancer Biology; Cancer Patient; Clinical; Clinical Trials; Complex; Diagnosis; Drug Delivery Systems; Economic Burden; Freezing; Goals; Immunoassay; Immunohistochemistry; Individual; Investigation; Malignant Neoplasms; Maps; Medical Economics; Molecular Profiling; Newly Diagnosed; Normal tissue morphology; Organ; Patients; Proteins; Proteome; Proteomics; Research; Solid; Solid Neoplasm; Techniques; Testing; Time; Tissues; Toxic effect; Treatment Efficacy; Tumor Tissue; cohort; evidence base; insight; molecular phenotype; novel strategies; tool; tumor

Our results have shown the ability to detect tumor residing proteins in the blood of a patient with a newly diagnosed non-metastatic cancer. In depth proteomic profiling of an individual patient's tumor for further elucidation of the particular molecular phenotype. A panel of putative markers are under investigation with high throughput techniques employing suitable immunoassays to test for general applicability to a much larger patient cohorts with this particular solid organ tumor. Such an approach facilitates maximization of therapeutic efficacy, minization of toxicities, and an attempt to reduce medical economic burdens. Further studies have now shown that a thin-tissue approach utilizing patient tumors, provide a discovery platform for key proteins involved in the individual patient's cancer. Many of these are drug targets. This new approach is nearly identical to the tissue and time requirements of IHC (immunohistochemistry), but is complementary. A major goal is to provide a new research tool for clinical trials, using this practical approach of molecular profiling on a protein level, with thin tissue sections from the patient's actual tumor.

我们的研究结果显示了检测新诊断的非转移性癌症患者血液中肿瘤驻留蛋白的能力。对个体患者的肿瘤进行深入的蛋白质组分析，以进一步阐明特定的分子表型。一组假定的标志物正在研究中，采用合适的免疫测定法，以测试对这种特定实体器官肿瘤的更大患者队列的普遍适用性。这种方法有助于最大化治疗效果，最小化毒性，并试图减少医疗经济负担。进一步的研究表明，利用患者肿瘤的薄组织方法为个体患者癌症中涉及的关键蛋白质提供了发现平台。其中许多是药物靶点。这种新方法与IHC（免疫组织化学）的组织和时间要求几乎相同，但具有互补性。一个主要目标是为临床试验提供一种新的研究工具，使用这种在蛋白质水平上进行分子分析的实用方法，使用来自患者实际肿瘤的薄组织切片。